An Open-label Study of XEN1101 in Epilepsy

Study Summary

This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 3 years.

Conditions

Focal Epilepsy Tonic-Clonic Seizures

Interventions / Drugs

XEN1101

View on ClinicalTrials.gov ↗

Sponsor

XENE

Xenon Pharmaceuticals

Ion Channel CNS

F34/100

Study Details

Enrollment880 participants

Primary Completion—

Lead SponsorXenon Pharmaceuticals Inc.

Data Retrieved2026-04-11 04:31:52.261401+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.